Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Sarepta has entered into a long-term strategic manufacturing partnership with Paragon, which will provide access to additional commercial manufacturing capacity for its micro-dystrophin DMD gene therapy program.
read more
Sarepta Therapeutics has entered into a long-term strategic manufacturing partnership with Brammer Bio.
read more
Catalent, Inc. and Sarepta Therapeutics, Inc. announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne ...
read more
Wednesday, March 27, 2013
Theorem Clinical Research, a full-service contract research organization (CRO) that provides core clinical research and development services, is pleased to announce the appointment of Sara Davis as vice president of global business development.
read more
Tuesday, October 15, 2024
Sapio Sciences announced the addition of new immunogenicity bioanalysis features to its lab informatics platform.
read more
Saphetor announced a research partnership with the Exome Consortium of Link (UCL), led by Dr. Vincent Plagnol.
read more
Sanyou Biopharmaceuticals announced the signing of a strategic cooperation agreement with Medicovestor a biotechnology company pioneering first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs).
read more
Sanofi and REVOLUTION Medicines announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cellular enzyme SHP2.
read more
Sanofi and Regeneron announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1, in patients with advanced CSCC.
read more
Recipharm and Sanofi announced they have signed an agreement to transfer the Holmes Chapel site from Sanofi to Recipharm.
read more
Sanofi and MD Anderson Cancer Center announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune-therapies.
read more
Wednesday, October 28, 2020
Sanofi and GSK have signed a Statement of Intent with Gavi, the legal administrator of the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of eventual COVID-19 vaccines.
read more
Wednesday, February 24, 2016
Sanofi has announced that the license and development agreement between Sanofi and kaléo, formerly Intelliject Inc., the developer of Auvi-Q® (epinephrine injection, USP), will terminate later this year.
read more
Sanofi has entered into an agreement with Moderna, under which Sanofi will help manufacture Moderna´s COVID-19 vaccine.
read more
Tuesday, February 25, 2020
Sanofi plans to create a European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (APIs).
read more